Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$5.08 USD
-0.28 (-5.22%)
Updated May 14, 2024 04:00 PM ET
After-Market: $5.40 +0.32 (6.30%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Brokerage Reports
Emergent Biosolutions Inc. [EBS]
Reports for Purchase
Showing records 201 - 220 ( 237 total )
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q3:12 Preview Second Opinion - Adjusting Estimates from Previous Preview -
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q3:12 Earnings Preview - Seasonally Strong BioThrax Numbers Anticipated
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
September 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Light Q2 Revenues but Stronger Back-Half Anticipated
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q1 Seasonally Light Quarter as Anticipated - Focus Shifts to the TB Vaccine and TRU-016 as BioThrax Revenues Roll In - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q4:11 Update - Anticipate Lower Q1 Revenue to Increase Later In the Year - TRU-016 Data at ASH 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Regains Rights to TRU-016 and Initiates Phase II Trial In CLL; Data H1:13
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
American Society of Hematology Annual Meeting (ASH) 2011 Company Abstract
Provider: WEDBUSH SECURITIES INC.
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
5 Year, 44.75 Million Doses, $1.25 Billion BioThrax Contract Announced - Lowering PT to $31 from $37
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: September 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q2:11 Earnings Preview - Strong BioThrax Numbers Anticipated
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Sole Source RFP for 44.75 Million Doses of BioThrax Over 5 Years, Final Award Announcement Expected H2:11 - Increasing Price Target to $37 from $32
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Weakness Unwarranted, Quarter Was No Surprise. Strong Quarter Ahead, in our Opinion
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G